Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.

LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead receives positive CHMP opinions under accelerated review from EMA for twice-yearly lenacapavir for HIV prevention: Foster City, California Saturday, July 26, 2025, 13:00 Hr ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...